| ²é¿´: 752 | »Ø¸´: 5 | ||||
[½»Á÷]
°ïæ¿´¿´ÓйØÑо¿µ°°×ÖÊÏ໥×÷ÓõķÖÎö·½·¨ÎÊÌâ
|
||||
|
Ê×ÏÈÉùÃ÷£¬±¾È˲»¶®ÉúÎïѧ£¬ËùÒÔÎÄÏ×ÖÐÓйØÊµÑé·½·¨µÄÆðʼ¾ä²»Ì«Ã÷°×¡£ 1To determine whether the compounds inhibited bromodomain-histone binding we utilized a peptide displacement assay based on AlphaScreen technology. Õâ¾ä»°ÖУ¬Ö÷ÒªÊDzÉÓá°Ê²Ã´·½·¨£¿ÉúÎïµÄ²»¶®£¬Çë¸øÓë½âÊÍ¡±²â¶¨»¯ºÏÎïÒÖÖÆäåÓòµ°°×-×é°±ËáµÄ½áºÏ×÷Óᣠ2 to investigate the selectivity of these compounds against other bromodomain, we employed a binding assay based on protein stablity shift. Õâ¾ä»°£¬ÒÀ¾ÉÊǺó°ë¾ä£¬ÉúÎïѧµÄ·ÖÎö·½·¨£¬²»¶®£¬ÐèÒª¸÷λ°ïÎÒɨä¡£ 3 To order to confirm that the dimethylisoxazole moiety was acting as a KAc minic and to elucidate structure-activity profiles for these compounds , we obtained the cocrystal structures of -------. Õâ¾ä»°¾ÍÊÇKAcÊÇɶËõд°¡¡£ ÁíÍ⣬ÓйضԵ°°×ÒÖÖÆ×÷ÓõÄ×ø±êͼÖУ¬ Y-×ø±ê£¨RLUs£©ºÍX-×ø±ê(Dose)·Ö±ð´ú±íʲôº¬Ò壬ͼÌù²»ÉÏÈ¥°¡¡£ |
» ÊÕ¼±¾ÌûµÄÌÔÌûר¼ÍƼö
·Ö×ÓÉú»¯ÊµÑé¾Ñé»ýÀÛ |
» ²ÂÄãϲ»¶
µ°°×Öʼì²â£º¾«×¼·ÖÎö£¬½âËøÉúÎï·Ö×ÓµÄÃÜÂë
ÒѾÓÐ0È˻ظ´
²»ºÏÀíÍÜ¿ÆÑÐʵÑé֮СÊóʵÑ飺ÑϽ÷Éè¼Æ£¬½âÎöÉúÃü»úÖÆµÄÖØÒªÔØÌå
ÒѾÓÐ0È˻ظ´
»¯Ñ§¹¤³Ì¼°¹¤Òµ»¯Ñ§ÂÛÎÄÈóÉ«/·ÒëÔõôÊÕ·Ñ?
ÒѾÓÐ100È˻ظ´
²»ºÏÀíÍÜ¿ÆÑÐʵÑéÖ®ÖØ½ðÊô¼ì²â£º¾«×¼É¸²é£¬ÊØ»¤½¡¿µÓë»·¾³µÄ·ÀÏß
ÒѾÓÐ0È˻ظ´
²»ºÏÀíÍÜ¿ÆÑÐʵÑéÖ®¡°ÍܲâÖØ½ðÊôÎÒ±³¹øÈýǧ¡±
ÒѾÓÐ0È˻ظ´
²»ºÏÀíÍÜ¿ÆÑÐʵÑéÖ®¡°ÊóÌÓÈý´ÎÎÒ·¢ÈýƪSCI¡±
ÒѾÓÐ0È˻ظ´
ÄÉÃ×Á£¶È·ÖÎö
ÒѾÓÐ3È˻ظ´
ÁÖ¿ÆÔºÁÖ»¯ËùÕÐÊÕ²ÄÁÏÓ뻯¹¤×¨ÒµË¶Ê¿£¬×ø±êÄϾ©
ÒѾÓÐ0È˻ظ´
Áôѧ--²©Ê¿ÕÐÉú
ÒѾÓÐ15È˻ظ´
»¯Ñ§¹¤³Ì£¬±¾211£¬Çóµ÷¼Á£¬abÇø²»ÏÞ
ÒѾÓÐ4È˻ظ´
» ±¾Ö÷ÌâÏà¹Ø¼ÛÖµÌùÍÆ¼ö£¬¶ÔÄúͬÑùÓаïÖú:
µ°°×ÖÊÖ®¼äÏ໥×÷ÓõÄÑо¿·½·¨ÓÐÄÄЩ£¿
ÒѾÓÐ3È˻ظ´
ÄÄλ°ï°ïæ°¡£¿¹ØÓÚµ°°×µÄÎÊÌâ
ÒѾÓÐ5È˻ظ´
Çë´ó¼Ò°ïæ¿´¿´Îҵĵ°°×µçӾͼ£¬Ð»Ð»´ó¼ÒÁË
ÒѾÓÐ10È˻ظ´
ϸ°ûÄÚµ°°×ÖʵÄÇ×ÊèË®ÐÔµÄÎÊÌ⣬´ó¼ÒÀ´°ïæ¿´¿´¡£
ÒѾÓÐ7È˻ظ´
Ô²¶þÉ«Æ×¶Ô·ÖÎöµ°°×ÖÊÏ໥×÷ÓÃÓаïÖúÂð
ÒѾÓÐ5È˻ظ´
¹ØÓÚE-tag±ê¼Çµ°°×µÄ´¿»¯ÎÊÌ⣡~ÇóÖú£¬Ð»Ð»°ïæ~£¡
ÒѾÓÐ9È˻ظ´
´óϺÃǰïæ¿´¿´3ºÍ4ÕâÁ½¸öµ°°×ÓÃʲôÑùµÄÖù×ÓÌîÁÏÄÜ·Ö¿ª
ÒѾÓÐ10È˻ظ´
°ïæ¿´¿´Éó¸åÒâ¼û£ºÓйطÖ×Ó¶¯Á¦Ñ§Ä£Äâ½âÊ͵°°×Óëµ×ÎïÏ໥×÷ÓÃ
ÒѾÓÐ3È˻ظ´
µ°°×ÖÊÏ໥×÷Óã¿
ÒѾÓÐ4È˻ظ´
´ó¼Ò°ïæ·ÖÎöÒ»ÏÂÎҵĵ°°×´¿»¯Ê±³öÏÖµÄÎÊÌâ°É£¬²»Ê¤¸Ð¼¤
ÒѾÓÐ5È˻ظ´
Çóµ°°×ÖÊÏ໥×÷ÓÃÑо¿·½·¨...
ÒѾÓÐ12È˻ظ´
µ°°×²¹²Ð»ù£¬¸÷λ°ï°ï濴ϰ¡£¡
ÒѾÓÐ11È˻ظ´
¡¾ÇóÖú¡¿¼¦µ°µÄµ°°×ÖÊŨ¶ÈÎÊÌ⣡£¡¸÷λ´óÏÀÇë°ï棡£¡
ÒѾÓÐ3È˻ظ´
¡¾ÇóÖú/½»Á÷¡¿¹ØÓÚQÖù·ÖÀëµ°°×µÄÎÊÌâ~¸ßÊÖ°ï°ïæ~
ÒѾÓÐ7È˻ظ´
» ÇÀ½ð±ÒÀ²£¡»ØÌû¾Í¿ÉÒԵõ½:
Öйú¿ÆÑ§ÔºÇൺÉúÎïÄÜÔ´Óë¹ý³ÌÑо¿Ëù ÕÐÉú2-3ÃûÁªÅàÉú
+1/181
¸£½¨Ê¦·¶´óѧҶӦÏé¿ÎÌâ×éÕÐÊÕ2026¼¶²©Ê¿Ñо¿Éú
+2/124
ÉϺ£µçÁ¦´óѧÏȽø´¢ÄÜµç³Ø¼¼Êõ¿ÎÌâ×éÕÐÉú
+1/92
ÄÏ·½Ò½¿Æ´óѧÖÐҩѧԺ µ÷¼Á˶ʿÉúÒ»Ãû ÖÐҩѧרҵ
+1/84
Î÷ÄϽ»Í¨´óѧҽѧԺÕÐÊÕÉúÎïҽѧ¹¤³ÌºÍ²ÄÁÏÓ뻯¹¤×¨ÒµË¶Ê¿Ñо¿Éú
+1/78
É¢½ð±Ò£¬Çó»ù½ðÖб꣡£¡
+1/58
¡¾È«¶î½±Ñ§½ð+Ó¢¹ú²©Ê¿Ñ§Î»¡¿¹ú¿Æ´óº¼¸ßÔºNathan¿ÎÌâ×éÕÐÊÕ2026¼¶ÁªÅ಩ʿÉú1Ãû£¡
+1/46
½ËտƼ¼´óѧÄÜÔ´²ÄÁÏ»¯Ñ§¿ÎÌâ×é¹ùÐË÷½ÌÊÚÕÐÊÕ²©Ê¿Ñо¿Éú1-2Ãû
+1/41
Çò²îÏà¹ØÖªÊ¶
+1/41
2026 ÎïÀí·½ÏòÕÐÊÕ²¿·Öµ÷¼Á
+1/33
¡¾ÊµÕ½ÐÍ¡¿¡¾ÉúÎïÒ½Ò©¡¿2026Çൺ´óѧÕв©Ê¿Éú º¬ÉÙÊýÃñ×å¹Ç¸É¼Æ»®2Ãû£¡
+1/15
Ìì½òÒ½¿Æ´óѧ»ù´¡Ò½Ñ§ÔºÕźã¿ÎÌâ×鲩ʿºóÕÐÆ¸
+1/9
¹þ¹¤´óºÕÏþ¶«ÔºÊ¿ÍŶÓË峬½ÌÊÚÕÐÊÕ²ÄÁÏѧ²©Ê¿1Ãû
+1/9
ºþÄÏũҵ´óѧ »·¾³¿ÆÑ§Ó빤³Ì0830+×ÊÔ´Óë»·¾³×¨Ë¶0857 µ÷¼ÁÃû¶î
+1/8
´óÁ¬Àí¹¤´óÑ§ÆøÌå¼à²âÓë»·¾³´ß»¯ÍÅ¶Ó³ÏÆ¸¸±½ÌÊÚ¡¢ÖúÀí½ÌÊÚ¼°²©Ê¿ºó3-4Ãû
+1/7
½ÌÓý²¿³¤½Ñ§Õߺʹ´ÐÂÍŶӷ¢Õ¹¼Æ»®¡±ÈëÑ¡ÍŶÓÕÐÊÕ ²ÄÁÏ£¬»¯Ñ§Ó뻯¹¤²©Ê¿Ñо¿Éú
+1/6
»¶Ó¸÷λͬѧÉêÇë²Î¼Ó°ÄÃÅ´óѧ½¡¿µ¿ÆÑ§Ñ§ÔºµÄ2026ÄêÏÄÁîÓª£¬±¨Ãû½ØÖ¹4ÔÂ12ºÅ
+1/6
ѰÕÒ26²©Ê¿Éúµ¼Ê¦
+1/6
¡¾²©Ê¿ÕÐÉú¡¿Ìì½òÀí¹¤´óѧ¹ú¼Ò½ÜÇàÍõÌú¿ÎÌâ×éÕÐÊÕ2026Ä격ʿÑо¿Éú
+1/4
26ÄêÕÐÊÕ07 08ѧÊõÐÍ/רҵÐÍ˶ʿÑо¿Éú
+1/3
¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï
Сľ³æ: ½ð±Ò+0.5, ¸ø¸öºì°ü£¬Ð»Ð»»ØÌû
cz_rubygd: ½ð±Ò+4, лл£¬protein stablity shiftÊÇʲôÇé¿ö£¿ 2013-01-06 22:54:33
Сµ¤Ä¾Ä¾: ½ð±Ò+3, ¹ÄÀø½»Á÷ 2013-01-07 16:30:31
Сľ³æ: ½ð±Ò+0.5, ¸ø¸öºì°ü£¬Ð»Ð»»ØÌû
cz_rubygd: ½ð±Ò+4, лл£¬protein stablity shiftÊÇʲôÇé¿ö£¿ 2013-01-06 22:54:33
Сµ¤Ä¾Ä¾: ½ð±Ò+3, ¹ÄÀø½»Á÷ 2013-01-07 16:30:31
|
ÄãÕâÆªÎÄÕµÄʵÑéÐԷdz£Ç¿£¬ÓеãÏñС×ÛÊö¡£Éæ¼°µÄ¼¼Êõ½Ï¶à£¬ 1. alpha Screen: http://www.proteomebinders.org/meetings/alpbach/talks/Chevet.pdf 2.A bromodomain is a protein domain that recognizes acetylated lysine residues such as those on the N-terminal tails of histonesËùÒÔÊDzⶨ»¯ºÏÎï¶ÔBromodomain»îÐÔµÄÒÖÖÆ×÷Óà 3.ÕâÊÇÑо¿µ°°×½á¹¹ÐÔÖʵķ½·¨£¬¿ÉÒÔÔĶÁ±¾ÎÄhttp://www.ncbi.nlm.nih.gov/pubmed/21674662 4.µÚÈýµã£¬°®ÄªÄÜÖú£¬Ëõд̫¶à£¬¶øÇÒûͼ²»ÄÜÅÐ¶Ï |
2Â¥2013-01-06 14:15:04
ccharlien
ľ³æ (ÕýʽдÊÖ)
- MolEPI: 1
- Ó¦Öú: 82 (³õÖÐÉú)
- ½ð±Ò: 2630.1
- Ìû×Ó: 334
- ÔÚÏß: 180.3Сʱ
- ³æºÅ: 1168776
¡ï ¡ï ¡ï ¡ï ¡ï
Сľ³æ: ½ð±Ò+0.5, ¸ø¸öºì°ü£¬Ð»Ð»»ØÌû
cz_rubygd: ½ð±Ò+2, лл 2013-01-06 22:54:27
Сµ¤Ä¾Ä¾: ½ð±Ò+2, ¹ÄÀø½»Á÷ 2013-01-07 16:30:47
Сľ³æ: ½ð±Ò+0.5, ¸ø¸öºì°ü£¬Ð»Ð»»ØÌû
cz_rubygd: ½ð±Ò+2, лл 2013-01-06 22:54:27
Сµ¤Ä¾Ä¾: ½ð±Ò+2, ¹ÄÀø½»Á÷ 2013-01-07 16:30:47
|
3. ʵÑéÊÒÀïKAc Ò»°ãÊÇ´×Ëá¼ØµÄËõд£¨Potassium acetate£©£¬Ã»ÓÐÉÏÏÂÎÄ£¬²»È·¶¨ RLUsÒ»°ãÊÇRelative Luciferase UnitsµÄËõд Dose¾ÍÊÇÊÔ¼ÁµÄ¼ÁÁ¿ ¿´ÆðÀ´ÊÇÓÃÁËÒ»¸ö±¨¸æ»ùÒòÊÔÑéÖ¤Ã÷¼ÁÁ¿¶Ô»îÐԸıäµÄÓ°Ïì |
3Â¥2013-01-06 20:57:27
¡ï ¡ï ¡ï
Сľ³æ: ½ð±Ò+0.5, ¸ø¸öºì°ü£¬Ð»Ð»»ØÌû
cz_rubygd: ½ð±Ò+2, лл£¡Âé·³½üÁ½Ìì¹Ø×¢ÎÒÔÚÉúÎï°å¿éµÄÆäËûÇóÖúÌû£¬¹ØÓÚ·Ö×Ó¶Ô½ÓµÄ 2013-01-07 13:09:30
Сľ³æ: ½ð±Ò+0.5, ¸ø¸öºì°ü£¬Ð»Ð»»ØÌû
cz_rubygd: ½ð±Ò+2, лл£¡Âé·³½üÁ½Ìì¹Ø×¢ÎÒÔÚÉúÎï°å¿éµÄÆäËûÇóÖúÌû£¬¹ØÓÚ·Ö×Ó¶Ô½ÓµÄ 2013-01-07 13:09:30
| KAc, ÄãµÃ¿´¿´ÎÄÖÐÊÇ·ñÏà·û¡£ÎÒ¸øÄãµÄÎÄÏ×ÓÐһƪ¾ÍÊÇ×östability shift¡£ ÀýÈ磬ÄãÓÃÈȱäÐÔÀ´¿¼²ìµ°°×Îȶ¨ÐÔ£¬ ÓÉÓÚÌõ¼þµÄ¸Ä±ä£¬¼Óµ×Î µÃµ½µÄÇúÏßÓëÎÞµ×ÎïµÄ¾Í²»Ò»Ö¡£Õâ¾ÍÊÇÎȶ¨ÐÔÆ¯ÒÆ£¡ |
4Â¥2013-01-07 09:03:57
5Â¥2013-01-07 12:48:27
¼òµ¥»Ø¸´
tianyiliang36Â¥
2013-04-20 15:05
»Ø¸´













»Ø¸´´ËÂ¥